Aortic Stenosis Treatment Springfield Lakes: Expert Heart Valve Care 2025

Experiencing chest pain, shortness of breath, or fainting spells? Aortic Stenosis (AS) is the most common heart valve disease requiring intervention in developed countries. Early detection and appropriate treatment can dramatically improve symptoms and extend life.

Understanding Aortic Stenosis

Aortic Stenosis is a progressive heart valve disease where the aortic valve becomes narrowed, restricting blood flow from the left ventricle to the body and forcing the heart to work harder.

Severity Classification

Severity	Valve Area (cm²)	Mean Gradient (mmHg)	Peak Velocity (m/s)
Mild	>1.5	<20	<3.0
Moderate	1.0-1.5	20-40	3.0-4.0
Severe	<1.0	>40	>4.0
Very Severe	<0.6	>60	>5.0

Types of Aortic Stenosis

Degenerative (senile) – most common, age-related calcification
Bicuspid aortic valve – congenital abnormality
Rheumatic – post-inflammatory scarring
Congenital – various developmental abnormalities

Causes and Risk Factors

Age-Related Degeneration

Most common cause – in patients >65 years
Calcium deposits – accumulate on valve leaflets
Progressive stiffening – valve becomes immobile
Prevalence – affects 3-5% of population >75 years

Bicuspid Aortic Valve

Congenital condition – valve has 2 instead of 3 leaflets
Earlier onset – symptoms typically in 50s-60s
Family clustering – genetic component
Associated conditions – aortic root dilation, coarctation

Risk Factors

Advanced age – strongest predictor
Male gender – 2:1 male predominance
Hypertension – accelerates valve degeneration
Diabetes – increases calcification risk
Smoking – accelerates atherosclerosis
Chronic kidney disease – calcium-phosphate imbalance

Symptoms and Clinical Presentation

Classic Triad

Chest pain (angina) – due to reduced coronary flow
Shortness of breath – heart failure symptoms
Syncope/presyncope – fainting or near-fainting

Early Symptoms

Exercise intolerance – reduced stamina
Fatigue – decreased energy levels
Palpitations – awareness of heartbeat
Dizziness – especially with exertion

Advanced Symptoms

Heart failure – fluid retention, severe dyspnea
Angina at rest – chest pain without exertion
Orthopnea – difficulty breathing when lying flat
Paroxysmal nocturnal dyspnea – awakening breathless

Physical Examination

Harsh systolic murmur – radiates to neck
Delayed carotid upstroke – pulsus parvus et tardus
Narrow pulse pressure – small difference between systolic/diastolic
Displaced apex beat – left ventricular hypertrophy
S4 gallop – due to stiff left ventricle

Diagnosis and Assessment

Echocardiography

Gold standard – definitive diagnosis and severity assessment
Valve area calculation – continuity equation
Gradient measurement – pressure difference across valve
Left ventricular function – ejection fraction assessment
Other valve assessment – concurrent valve disease

Cardiac Catheterization

Coronary angiography – assess for coronary artery disease
Hemodynamic assessment – direct pressure measurements
Pre-operative evaluation – before valve replacement
Complex cases – when echo findings unclear

Additional Testing

ECG – left ventricular hypertrophy, conduction abnormalities
Chest X-ray – cardiac silhouette, pulmonary congestion
Exercise stress test – symptom assessment in asymptomatic patients
CT calcium scoring – quantify valve calcification
Cardiac MRI – if echo images suboptimal

Risk Stratification

Symptoms – most important predictor
Valve severity – hemodynamic assessment
Left ventricular function – ejection fraction
Exercise tolerance – functional capacity
Rate of progression – serial echocardiograms

Treatment Options

Medical Management

Symptomatic relief – diuretics for heart failure
Blood pressure control – careful management
Arrhythmia management – if atrial fibrillation present
Avoid vasodilators – can cause hypotension
Infection prevention – dental hygiene important

Surgical Aortic Valve Replacement (SAVR)

Gold standard – for suitable surgical candidates
Mechanical valves – lifelong anticoagulation required
Biological valves – limited durability but no anticoagulation
Mortality – 1-3% in experienced centers
Recovery – 6-8 weeks typical

Transcatheter Aortic Valve Replacement (TAVR)

Minimally invasive – catheter-based approach
High-risk patients – alternative to surgery
Expanding indications – now used in intermediate and low-risk
Recovery – 1-3 days hospital stay
Complications – stroke, conduction abnormalities, paravalvular leak

Treatment Decision Making

Patient Profile	Recommended Treatment	Considerations
Low surgical risk	SAVR or TAVR	Patient preference, anatomy
Intermediate risk	SAVR or TAVR	Heart team decision
High surgical risk	TAVR	If technically feasible
Prohibitive risk	Medical management	Palliative care

Timing of Intervention

Symptomatic Severe AS

Immediate referral – for valve replacement
Class I indication – clear benefit established
Mortality – high without intervention
Symptom resolution – dramatic improvement expected

Asymptomatic Severe AS

Exercise testing – assess functional capacity
Serial monitoring – every 6-12 months
Early surgery – if LVEF <50%, very severe AS
Watchful waiting – if truly asymptomatic

Moderate AS

Regular monitoring – annual echocardiogram
Symptom assessment – exercise testing if needed
Progression rate – 0.1-0.3 cm²/year valve area decrease
Risk factors – age, calcium burden predict progression

Post-Procedure Care

Immediate Recovery

ICU monitoring – first 24-48 hours
Hemodynamic monitoring – blood pressure, heart rhythm
Anticoagulation – temporary after TAVR
Mobilization – early ambulation encouraged
Complications – bleeding, conduction abnormalities

Long-term Follow-up

Echo at discharge – baseline post-procedure
30 days – clinical and echo assessment
Annual follow-up – lifelong monitoring required
Valve durability – bioprosthetic valves degenerate over time
Anticoagulation – if mechanical valve or atrial fibrillation

Activity Restrictions

Driving – resume after 1-2 weeks (TAVR), 6-8 weeks (SAVR)
Exercise – gradual return to activities
Travel – no restrictions after recovery
Work – return based on job requirements
Sexual activity – resume when comfortable

Complications and Prognosis

Untreated Severe AS

50% mortality – at 2 years once symptomatic
Sudden cardiac death – 15-20% annual risk
Heart failure – progressive left ventricular dysfunction
Arrhythmias – atrial fibrillation common
Stroke – increased risk with concurrent atrial fibrillation

Post-Intervention Outcomes

Symptom improvement – 90-95% experience relief
Survival benefit – significant mortality reduction
Quality of life – marked improvement in most patients
Exercise capacity – gradual return to normal activities
Long-term durability – 15-20 years for bioprosthetic valves

Potential Complications

Stroke – 2-5% risk with TAVR
Pacemaker requirement – 10-15% with TAVR
Paravalvular leak – more common with TAVR
Bleeding – anticoagulation-related
Prosthetic valve dysfunction – structural deterioration over time

Take Action: AS Care

Don’t let aortic stenosis symptoms limit your life. Health Hub Springfield Lakes provides comprehensive heart valve evaluation and coordinates specialist care.

Book Your Heart Valve Assessment

Online booking: Available 24/7 at healthhubspringfieldlakes.com.au/
Phone booking: Call +61 7 3778 4888
Urgent consultation: Same-day appointments for concerning symptoms
Specialist referrals: Direct cardiothoracic surgery connections

Address: 18 Springfield Lakes Blvd, Springfield Lakes QLD 4300
Your trusted partner for aortic stenosis care and heart valve management.

Medical References

Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143(5):e72-e227.
Therapeutic Guidelines Limited. Cardiovascular: Aortic stenosis. In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2023.
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561-632.
Australian Government Department of Health. National Heart Foundation Clinical Practice Guidelines for Valvular Heart Disease. Canberra: Commonwealth of Australia; 2021.
Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016;374(17):1609-1620.
Playford D, Strange G, Celermajer DS, et al. Aortic stenosis in Australia: clinical characteristics and outcomes from the National Echo Database Australia (NEDA). Med J Aust. 2020;213(9):401-407.
National Heart Foundation of Australia. Position Statement on Transcatheter Aortic Valve Implantation. Melbourne: National Heart Foundation of Australia; 2020.
Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation. 2010;121(1):151-156.
Royal Australian College of General Practitioners. Recognition and management of aortic stenosis in general practice. Melbourne: RACGP; 2021.
Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. Eur Heart J. 2021;42(19):1825-1857.

Medical Disclaimer: This information is for educational purposes and does not replace professional medical advice. If you’re experiencing chest pain, shortness of breath, or fainting spells, seek immediate medical attention. Health Hub Springfield Lake’s medical team provides comprehensive aortic stenosis evaluation and specialist referrals.